EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Integrating Pharmacogenomics into the Beers Criteria: A Machine Learning-driven Risk Assessment Framework for Novel Gene Drug Interactions

Abdulrhman Salem Al-Harthy, Manar Abaas Alhejji, Zainab Ibrahim Albeladi, Turki Khalid Alsaud, Hawra Ali Hasan Yahya, Fatema Ahmed Ali Jasim, Ahmed Abdullah Omar Jahlan, Ali Mohsen Klebe, Amer Mohammed Asiri, Mohammad Al Mohaini

Journal of Advanced Trends in Medical Research · 2025

DOI: 10.4103/atmr.atmr_100_25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Advanced Trends in Medical Research, 2025. Verfasst von Abdulrhman Salem Al-Harthy und 9 weiteren Autor:innen. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The Beers Criteria are widely used to identify potentially inappropriate medicines (PIMs) in older adults. However, it does not account for pharmacogenomic variability, which can lead to adverse drug reactions (ADRs) in genetically susceptible individuals. This study aimed to develop and validate a machine learning–driven framework that integrates pharmacogenomic data into the Beers Criteria to support personalized prescribing and reduce ADR risk.

Methods

We designed a hybrid neural network combining graph attention networks (GATs) and Transformers to predict clinically relevant drug–gene associations using multi-omics, pharmacogenomic and ADR datasets. In silico quantitative trait locus mapping was performed to validate predicted interactions, complemented by experimental validation using the luciferase reporter assays. Pharmacogenomic interactions confirmed through this process were proposed as contraindications for integration into the Beers Criteria. The framework was implemented using PyTorch Geometric and the Hugging Face Transformer library.

Results

The GAT-Transformer model achieved high predictive performance, with an area under the receiver operating characteristic curve of 0.92, area under the precision-recall curve of 0.87 and F1 score of 0.83 for 78 high-risk Beer’s medications, outperforming baseline models. Amongst 14,520 candidate drug–gene pairs, 327 novel interactions were predicted (false discovery rate < 0.05) and 31 were experimentally validated, yielding a validation rate of 73.8%.

Conclusion

This framework provides a scalable, evidence-based approach to integrate pharmacogenomics into PIM assessment, enhancing the Beers Criteria for genetically susceptible elderly populations. By identifying patient-specific risk factors for ADRs, it has the potential to improve medication safety and optimise geriatric pharmacotherapy outcomes.

Zitieren

APA

Al-Harthy, A. S., Alhejji, M. A., Albeladi, Z. I., Alsaud, T. K., Yahya, H. A. H., Jasim, F. A. A., Jahlan, A. A. O., Klebe, A. M., Asiri, A. M., & Mohaini, M. A. (2025). Integrating Pharmacogenomics into the Beers Criteria: A Machine Learning-driven Risk Assessment Framework for Novel Gene Drug Interactions. Journal of Advanced Trends in Medical Research. https://doi.org/10.4103/atmr.atmr_100_25

Vancouver

Al-Harthy AS, Alhejji MA, Albeladi ZI, Alsaud TK, Yahya HAH, Jasim FAA, et al. Integrating Pharmacogenomics into the Beers Criteria: A Machine Learning-driven Risk Assessment Framework for Novel Gene Drug Interactions. Journal of Advanced Trends in Medical Research. 2025. doi:10.4103/atmr.atmr_100_25

BibTeX
@article{AlHarthy2025,
  author = {Al-Harthy, Abdulrhman Salem and Alhejji, Manar Abaas and Albeladi, Zainab Ibrahim and Alsaud, Turki Khalid and Yahya, Hawra Ali Hasan and Jasim, Fatema Ahmed Ali and Jahlan, Ahmed Abdullah Omar and Klebe, Ali Mohsen and Asiri, Amer Mohammed and Mohaini, Mohammad Al},
  title = {Integrating Pharmacogenomics into the Beers Criteria: A Machine Learning-driven Risk Assessment Framework for Novel Gene Drug Interactions},
  journal = {Journal of Advanced Trends in Medical Research},
  year = {2025},
  doi = {10.4103/atmr.atmr_100_25}
}
Kostenlos starten →